BLRX (BioLine Rx) FCF Margin %: -479.25% (As of Mar. 2026)


BLRX BioLine Rx Ltd BLRX
23 GF Score
Price $3.07
! 5 Warning Signs
View Full Analysis

What is BioLine Rx FCF Margin %?

BioLine Rx BLRX -2.35% 23 FCF Margin % is -479.25% as of Mar. 2026. GuruFocus rates BLRX with a GF Score™ of 23/100. The stock has 5 warning signs investors should review. Among 959 Biotechnology companies, BioLine Rx ranks worse than 73.51% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BioLine Rx's Free Cash Flow for the three months ended in Mar. 2026 was $-2.29 Mil. BioLine Rx's Revenue for the three months ended in Mar. 2026 was $0.48 Mil. Therefore, BioLine Rx's FCF Margin % for the quarter that ended in Mar. 2026 was -479.25%.

As of today, BioLine Rx's current FCF Yield % is -58.80%.

The historical rank and industry rank for BioLine Rx's FCF Margin % or its related term are showing as below:

BLRX' s FCF Margin % Range Over the Past 10 Years
Min: -686.56   Med: -477.18   Max: -151.79
Current: -554.14

During the past 13 years, the highest FCF Margin % of BioLine Rx was -151.79%. The lowest was -686.56%. And the median was -477.18%.

BLRX's FCF Margin % is ranked worse than
73.51% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs BLRX: -554.14

BioLine Rx FCF Margin % Related Terms

BioLine Rx FCF Margin % Historical Data

* Premium members only.

The historical data trend for BioLine Rx's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLine Rx FCF Margin % Chart

BioLine Rx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -477.19 -151.79 -686.53

BioLine Rx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,016.08 -58.22 -493.21 -1,649.48 -479.25

BLRX vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, BioLine Rx's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's FCF Margin % distribution charts can be found below:

* The bar in red indicates where BioLine Rx's FCF Margin % falls into.


BLRX
23GF Score
BioLine Rx Ltd BLRX
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLine Rx FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

BioLine Rx's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-8.101/1.18
=-686.53 %

BioLine Rx's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-2.286/0.477
=-479.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -479.25% mean?
BioLine Rx (BLRX) has a FCF Margin % of -479.25% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BioLine Rx and its competitors. According to the industry distribution chart, BioLine Rx ranks #705 out of 959 companies in the Biotechnology industry, placing it in the top 73.5%.
Is BioLine Rx's FCF Margin % too high?
BioLine Rx's current FCF Margin % is -479.25%. Based on the distribution chart, BioLine Rx ranks #705 out of 959 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioLine Rx has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does BioLine Rx's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioLine Rx ranks #705 out of 959 companies for FCF Margin %. This places BioLine Rx in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BioLine Rx and its competitors. BioLine Rx's current FCF Margin % is -479.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLine Rx stock overvalued right now?
BioLine Rx (BLRX) has a current FCF Margin % of -479.25%. The current FCF Margin % is -479.25%. BioLine Rx's overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For BioLine Rx (BLRX), the current FCF Margin % is -479.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioLine Rx Business Description

Other Exchanges BLRX:IsraelYP2:Germany
Address 2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
23GF Score

Get the complete analysis for BLRX

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.07
Price